GlassScriptPhysician profile
Ankur Kumar Singh
NPI 1437680741
$1,872.24
in general payments reported to CMS, 2019-2025
35 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $461 · 2024: $1,179 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.25 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $160.90 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $143.99 | 2023-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $133.51 | 2023-2024 | |
| Janssen Biotech, INC. | $129.12 | 2023-2025 | Talvey, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $122.87 | 2023-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $117.63 | 2023-2024 | Lynparza, Tagrisso, Calquence |
| Alexion Pharmaceuticals, INC. | $92.54 | 2023-2024 | Ultomiris |
| Genentech USA, INC. | $82.87 | 2023-2024 | Venclexta, Tecentriq, Gazyva |
| Eisai INC. | $54.89 | 2023-2024 | |
| Tersera Therapeutics LLC | $51.79 | 2024-2025 | Zoladex |
| Takeda Pharmaceuticals U.S.A., INC. | $50.85 | 2024 | Ninlaro, Iclusig |
| Aveo Pharmaceuticals, INC. | $49.68 | 2024 | |
| Gilead Sciences, INC. | $46.76 | 2024 | |
| Incyte Corporation | $44.99 | 2023-2024 | Monjuvi, Jakafi, Pemazyre |
| Celgene Corporation | $44.04 | 2024 | Reblozyl, Pomalyst |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.45 | 2023-2025 | |
| Taiho Oncology, INC. | $40.32 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $38.88 | 2024 | Opdualag |
| Glaxosmithkline, LLC. | $37.60 | 2024 | Jemperli, Ojjaara, Zejula |
| Sobi, INC | $35.83 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $35.39 | 2023-2024 | Libtayo |
| Servier Pharmaceuticals LLC | $33.48 | 2024 | |
| Lilly USA, LLC | $33.27 | 2024-2025 | Jaypirca, Verzenio |
| Exelixis INC. | $29.09 | 2023-2024 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.72 | 2025 | |
| Genmab U.S., INC. | $25.69 | 2024 | Tivdak |
| Beigene USA, INC. | $24.18 | 2024 | Brukinsa, Tevimbra |
| Fennec Pharmaceuticals, INC. | $23.64 | 2025 | Fyarro |
| Genzyme Corporation | $21.48 | 2024 | |
| Array Biopharma INC | $19.48 | 2024 | Tukysa, Mektovi, Braftovi |
| Cti Biopharma Corp. | $18.32 | 2023 | Vonjo |
| Adc Therapeutics America, INC. | $15.35 | 2025 | |
| G1 Therapeutics, INC. | $14.95 | 2023 | Cosela |
| Astellas Pharma US INC | $14.17 | 2023 | Padcev |
| Agios Pharmaceuticals, INC. | $13.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.